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Abstract
Although antibiotics are a common treatment for acne, the difficulties inherent to effective 
antimicrobial penetration in sebum and selective antimicrobial action in skin are compounded by 
increasing resistance of Propionibacterium acnes clinical isolates. To address these problems, we 
engineered Pentobra, a peptide-aminoglycoside molecule which has multiple mechanisms of 
antibacterial action, and investigated whether it can be a potential candidate for the treatment of 
acne. Pentobra combines the potent ribosomal activity of aminoglycosides with the bacteria-
selective membrane-permeabilizing abilities of antimicrobial peptides (AMPs). Pentobra 
demonstrated potent and selective killing of P. acnes, but not against human skin cells in vitro. In 
direct comparison, Pentobra demonstrated bactericidal activity and drastically outperformed free 
tobramycin (by 5–7 logs) against multiple P. acnes clinical strains. Moreover, EM studies showed 
that Pentobra had robust membrane activity, as treatment with Pentobra killed P. acnes cells and 
caused leakage of intracellular contents. Pentobra may also have potential anti-inflammatory 
effects as demonstrated by suppression of some P. acnes-induced chemokines. Importantly, the 
killing activity was maintained in sebaceous environments as Pentobra was bactericidal against 
clinical isolates in comedones extracts isolated from human donors. Our work demonstrates that 
equipping aminoglycosides with selective membrane activity is a viable approach for developing 
antibiotics against P. acnes that are effective in cutaneous environments.
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Introduction
The commensal bacterium Propionbacterium acnes is a major etiological factor in acne 
vulgaris (McInturff et al., 2005; Ross et al., 2003; Williams et al., 2012). Although topical 
antibiotic therapies are used (Eady et al., 2003), increasing resistance have made acne 
treatment challenging. The incidence of P. acnes antibiotic resistance increased from 20% in 
1978 to 72.5% in 1995 (Humphrey, 2012); widespread resistance has become a major 
dermatological issue (Cooper, 1998; Eady et al., 2003; Humphrey, 2012; Williams et al., 
2012). Antibiotic resistance is compounded by the difficulties inherent to effective 
antimicrobial penetration in skin. Many antibiotics are charged and do not penetrate into the 
largely hydrophobic sebaceous environmental niche of P. acnes. Clearly, antibiotic therapies 
that are more tailored to these problems are needed.
It is difficult for an organism to simultaneously evolve resistance against multiple 
antimicrobial mechanisms. This observation has motivated the development of multi-drug 
strategies (antibiotic cocktails). While this approach has been effective for some diseases 
(i.e. leprosy), it has led to multi-drug resistant strains in others (i.e. tuberculosis), in part due 
to inherent problems from the use of multiple drugs. Rather than using a complex cocktail, 
we aim to engineer a P. acnes antibiotic by combining the potent ribosomal activity of 
aminoglycosides with the bacteria-selective membrane-permeabilizing abilities of 
antimicrobial peptides (AMPs), which can perforate prokaryotic membranes but not 
eukaryotic membranes. Aminoglycoside antibiotics target the 16S rRNA component of the 
bacterial ribosome leading to mistranslation, inhibition, and cell death (Fourmy et al., 1996; 
Vicens and Westhof, 2002). In vitro studies have shown that although aminoglycosides are 
usually potent antimicrobials, P. acnes is not strongly susceptible to them (Wang et al., 
1977). As P. acnes is an anaerobic bacterium, it is hypothesized that its intrinsic resistance is 
a result of poor aminoglycoside uptake, not a lack of ribosomal activity (Davis, 1987; Taber 
et al., 1987). AMPs can selectively permeabilize bacterial membranes (Brogden, 2005; 
Hancock and Sahl, 2006; Schmidt and Wong, 2013; Zasloff, 2002). While many AMPs kill 
via lysis, many others combine membrane activity with additional mechanisms such as 
inhibition of metabolic functions by binding intracellular targets (Brogden, 2005). 
Aminoglycosides equipped with cell-penetrating abilities can have activity against slow-
growing bacteria like P. acnes, which have little uptake. Moreover, the addition of AMP-
like membrane activity will add an extra dimension of selectivity to the specific mechanisms 
inherent to aminoglycosides.
Here we report an aminoglycoside-based compound with bactericidal activity against P. 
acnes. Our design is informed by recent work which elucidate the roles of cationic and 
hydrophobic residues in AMP sequences (Schmidt et al., 2011; Schmidt et al., 2012b), Cell-
penetrating peptide (CPP) sequences (Mishra et al., 2011), and non-peptidic AMP mimetic 
compositions (Hu et al., 2013; Schmidt et al., 2012a), and relate them to the geometric 
requirements of membrane permeabilization. Tobramycin, a potent aminoglycoside, is 
conjugated to a short 12AA peptide to equip the composite molecule, Pentobra (Figure 1A), 
with preferential activity against bacterial membranes like an AMP, so that the composite 
molecule has multiple levels of selectivity and multiple mechanisms of killing (Schmidt et 
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al., 2014). The work presented herein, demonstrates that equipping aminoglycosides with 
selective membrane activity is a viable approach for developing antibiotics against P. acnes 
that are effective in cutaneous environments.
Results
Pentobra has potent and selective antimicrobial activity against P. acnes, but not against 
human skin cells
Since Pentobra is designed to permeabilize membranes, we hypothesized that Pentobra 
should be bactericidal against P. acnes. We tested the killing potency of Pentobra against P. 
acnes using CFU assays (Figure 1B). Pentobra displayed dose-dependent killing activity 
against P. acnes laboratory strain ATCC 6919. Concentrations as low as 8 μM Pentobra 
produced a ten-fold reduction in viable colonies, and 26 μM Pentobra led to a 5-log 
reduction in CFU. In contrast, tobramycin was not strongly bactericidal, as concentrations as 
high as 52 μM led to less than ten-fold reduction in CFU. These data show that membrane-
active aminoglycosides can kill the P. acnes lab strain, whereas neither tobramycin nor the 
free pen peptides were effective. Importantly, Pentobra is not toxic to human skin cells as 
treatment did not affect the viability of human peripheral blood mononuclear cells (PBMCs), 
keratinoctyes, or sebocytes over 72 hrs (Supplementary Figure S1 A&B).
Pentobra is active against a wide variety of P. acnes clinical strains
The predominant microbe found in the microcomedone content is P. acnes, which accounts 
for ~90% of the microbiota (Fitz-Gibbon et al., 2013). Moreover, microcomedones from 
healthy vs. diseased skin harbor P. acnes strains from distinct lineages and possess distinct 
nucleopeptide signatures of 16S rDNA sequences. While some P. acnes strains are found on 
healthy skin (phylotype III and ribotype 6), others are associated with acne disease 
(ribotypes 4, 5, 8, and phylotype IC) and with diseases such as medical device infections 
(phylotype II) (McDowell et al., 2013). To examine the antimicrobial activity of Pentobra 
against different P. acnes strains (Table 1), we conducted CFU assays on clinical isolates. In 
general, Pentobra exhibited robust bactericidal activity against all tested P. acnes strains 
(Figure 2). Against P. acnes clinical isolates HL063PA2 (healthy) and HL005PA1 (healthy) 
(Figure 2A&B), greater than 5-log reductions in CFU were observed at 26 μM Pentobra. 
While strain HL110PA4 (healthy) was less susceptible (Figure 2C), a 2-log reduction 
occurred at the highest concentration tested. Interestingly, this differential activity may 
allow Pentobra to shift slightly the ecology of P. acnes toward strains associated with 
healthy skin. Pentobra also killed P. acnes strains HL053PA2, HL043PA1, and HL110PA1 
that are associated with acne skin (Figure 2D–F), as 13 μM Pentobra was sufficient to 
reduce CFU by greater than 5-log units for the first two strains and 3-log units for the third 
one. Similar to ATCC 6919, tobramycin did not exhibit significant antimicrobial activity 
against most of these clinical isolates, whereas the free pen peptide typically demonstrated 
moderate 2–3-log reductions in CFU. However, tobramycin was strongly bactericidal 
against strain HL005PA1, suggesting that aminoglycosides may be effective against certain 
strains of P. acnes. Our results demonstrate that Pentobra has potent activity against 
clinically relevant strains.
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Pentobra alters cell surface morphology, permeates and lyses P. acnes
Pentobra is designed to have selective membrane permeation activity similar to AMPs. To 
determine its effects on the cell envelope, we examined P. acnes treated with Pentobra using 
electron microscopy (Figure 3). Transmission EM micrographs of untreated P. acnes 
illustrate their normal pleomorphic structure (Figure 3A). After a 3 hour treatment with 
Pentobra, different types of cell envelope disruptions are observed (Figure 3B). Cell surfaces 
appear ruffled from blebbing, and complete breaches in the envelope are observed, with 
externalized cytoplasmic contents characteristic of lysis. These morphological changes are 
consistent with those from membrane active molecules. The observed robust 
permeabilization of P. acnes membranes corresponds well with previous x-ray studies, 
which showed that Pentobra generates disruptive membrane curvatures in model bacterial 
cell membranes and permeabilizes E. coli inner membranes (Schmidt et al., 2014). To see 
how the different components of Pentobra impact P. acnes, EM studies were performed with 
free pen peptide and tobramycin. The pen peptide is lytic (Figure 3C), which is consistent 
with its strong membrane permeabilization profiles on E. coli cells (Schmidt, 2014). P. 
acnes treated with tobramycin are indistinguishable from control (Figure 3D), in line with 
our antibacterial assays and with the reduced uptake of aminoglycosides into anaerobic 
bacteria cells.
Pentobra maintains antimicrobial activity in human comedone extracts
Acne therapeutics must maintain activity in lipid-rich environments. To assay the 
effectiveness of Pentobra against clinical isolates in sebaceous environments, we used 
comedone extracts isolated from human donors as an in vitro model (Figure 4). Pentobra 
showed dose-dependent bactericidal activity against P. acnes in comedone extracts from 
four donors, producing 5-log (Figure 4A&B), 3-log (Figure 4C), and 6-log (Figure 4D) 
reductions in CFUs. In contrast, tobramycin and the pen peptide alone were significantly 
less effective. That Pentobra is amphiphilic may contribute significantly to the enhanced 
activity in strongly hydrophobic environments. The amphiphilic peptide moiety of Pentobra 
has at least two beneficial effects: it drastically increases the activity of aminoglycoside 
antibiotics against P. acnes, and the lipophilicity aspect of Pentobra allows it to maintain 
activity in sebaceous environments.
Immunomodulatory effect of Pentobra and tobramycin in human monocytes
To determine if Pentobra has an immunomodulatory effect on host innate immune response, 
we isolated and co-treated human monocytes and keratinocytes with P. acnes in the 
presence of either Pentobra or tobramycin, and measured cytokine and chemokine 
expression levels by ELISA and real time PCR. P. acnes induced the expression of MCP-1, 
CCL22, IP-10 and IL-12p40 in both cell types (Figure 5) which in monocytes could be 
inhibited (40–100%) by both Pentobra and tobramycin except for IL-12p40 gene expression, 
where both antibiotics demonstrated little to no inhibition of IL-12p40 by P. acnes-
stimulated monocytes. Tobramycin was more effective in inhibiting MCP-1 expression in 
monocytes compared to Pentobra. Both antibiotics completely abrogated P. acnes–induced 
IP-10 expression (p<0.001) in monocytes and keratinocytes. In contrast, no significant 
change in IL-6, IL-8, TNF-α and IL-12p40 cytokine production was found in P. acnes–
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activated monocytes in the presence of both antibiotics (Supplementary Figure S2 and data 
not shown). Therefore, both Pentobra and tobramycin appear to modulate specific cytokine 
and chemokine production induced by P. acnes but not all cytokines and chemokines that 
have been reported to play a role in the formation of inflammatory acne lesions. (McInturff 
et al., 2005; Vowels et al., 1995a; Vowels et al., 1995b)
Discussion
The increasing antibiotic resistance in clinical isolates of P. acnes highlights the need for 
new therapeutic strategies. The performance of Pentobra against P. acnes suggests that 
equipping aminoglycosides with the ability to permeate membranes in the manner of AMPs 
can be broadly enabling. Aminoglycosides are known to generally target bacterial ribosomes 
by binding the decoding aminoacyl site on the 16S rRNA component of the 30S ribosomal 
subunit, leading to faulty protein translation and inhibition (Fourmy et al., 1996; Vicens and 
Westhof, 2002). This mechanism of action is potent and highly bactericidal against many 
types of clinically relevant bacteria. Empirically, aminoglycosides are known to have little 
effectiveness on P. acnes (Dréno et al., 2004; Wang et al., 1977; Williams et al., 2012) and 
other anaerobic bacteria. Aminoglycosides bind the ribosomes of anaerobic bacteria and 
bacteria that use oxygen with similar affinities (Bryan et al., 1979). It is therefore 
hypothesized that anaerobic bacteria are intrinsically resistant to aminoglycosides because 
the molecules cannot cross the cytoplasmic membranes of anaerobic cells to reach the 
bacterial ribosome (Allison et al., 2011; Taber et al., 1987). The lower proton-motive force 
(PMF) (Davis et al., 1986; Magnet and Blanchard, 2004) across the membranes of anaerobic 
bacteria in comparison with oxygen-using bacteria impairs internalization, since 
aminoglycoside uptake is proposed to be energy-dependent from reliance on a threshold 
PMF (Allison et al., 2011; Davis, 1987; Magnet and Blanchard, 2004; Taber et al., 1987). 
Although the general AMP membrane permeabilization mechanism is broad spectrum 
(Schmidt and Wong, 2013), and their activities are less sensitive to the metabolic status of 
the cell (Hurdle et al., 2011), AMPs often only display moderate potency. When juxtaposed, 
the distinct mechanisms of action of aminoglycosides and AMPs become complementary. 
Hybrid membrane-active aminoglycosides can kill bacteria by membrane disruption, and 
can also enter cells and interfere with ribosome translation. The direct killing of all tested P. 
acnes clinical isolates by Pentobra shows that our approach has promising general 
therapeutic value.
Bacteria must simultaneously evade both of pentobra’s killing mechanisms to develop 
resistance, similar to drug combination therapies used to minimize chances of bacterial 
resistance (Fischbach, 2011; Walsh, 2000; Worthington and Melander, 2013). While 
bacteria have well-developed pathways to decrease susceptibility to AMPs through 
phenotypic changes (Guo et al., 1997; Koprivnjak and Peschel, 2011; Li et al., 2007), these 
mechanisms do not usually confer complete resistance (Hancock and Sahl, 2006). This is 
believed to be a result of the ability of AMPs to target generic properties in the lipid 
composition of bacterial membranes (Hancock and Sahl, 2006; Schmidt and Wong, 2013; 
Zasloff, 2002). In fact, to evolve AMP resistance by eliminating these generic lipid 
properties of bacterial membranes amounts to a lethal mutation (Yang et al., 2008). By 
multiplexing the specificity of ribosomal activity from tobramycin with the general 
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susceptibility of bacterial membranes to AMPs, Pentobra provides potent antimicrobial 
activity with reduced likelihood of P. acnes resistance.
A topical antimicrobial therapy must penetrate lipid-rich media and maintain activity in 
cutaneous environments. The initial stage of acne infection is a microcomedone, and 
previous work has used extracted microcomedone contents to determine the effectiveness of 
antimicrobial therapies for acne (Piérard-Franchimont et al., 2002). We performed similar 
microcomedone experiments to determine if Pentobra, which is amphipathic, can penetrate 
hydrophobic environments and remain active when presented with lipidic material from 
skin. Hydrophilic drugs like aminoglycosides may not be able to penetrate through the 
layers of fatty acids in human skin, while overly hydrophobic drugs may become 
irreversibly sequestered with fatty acids and will be unavailable to act on P. acnes. Our 
assays on P. acnes isolated from microcomedones show that Pentobra can kill P. acnes in a 
sebum-rich environment. Human skin widely expresses cathelicidin LL37 (Dürr et al., 
2006), as well as defensins HBD-2 (Harder et al., 1997) and HBD-3 (Harder et al., 2001), 
which suggests that AMPs can offer protection in skin against microbial colonizers, and 
AMP gene knock out studies have shown these animals are more vulnerable to infection 
(Bowdish et al., 2006; Dürr et al., 2006). Many membrane-permeabilizing AMPs including 
HBD2 (Bals et al., 1998) and LL37 (Dürr et al., 2006) show loss of antimicrobial activity in 
elevated salt concentrations in vitro. Like these AMPs the bactericidal activity of Pentobra 
against P. acnes is attenuated with increasing sodium chloride concentrations (Panel C of 
supplementary Figure S1). This affords future engineering possibilities: While plate killing 
assays provide important measures of drug potency, it does not always mirror the 
performance of a drug in vivo. In principle, it is possible to engineer membrane-active 
aminoglycosides that are not as salt sensitive because some AMPs have in vitro salt tolerant 
antibacterial profiles (Harder et al., 2001). Furthermore, drug activities can be modulated by 
formulation and method of delivery. Overall, the microcomedone experiments highlight the 
efficacy of Pentobra in lipid-rich cutaneous environments, which is suggestive of its utility 
as a topical antimicrobial agent.
For a clear understanding of the immunomodulation by Pentobra, we explored its function at 
the transcriptional and protein levels. Many mammalian AMPs have immunomodulatory 
functions (Bowdish et al., 2006). For example, human cathelicidin LL37 can decrease 
cytokine production in response to LPS (Scott et al., 2002), which is a ligand for TLR4. 
Previous studies have proposed that the anti-endotoxin abilities of implicated cathelicidins 
are partly due to direct binding between the cationic peptides and anionic LPS (Rosenfeld 
and Shai, 2006; Scott et al., 2000), since the neutralized LPS is unavailable to associate with 
pattern recognition receptors. The 12AA pen peptide is derived from the protein 
transduction domain of the Drosophila antennapedia homeodomain (Derossi et al., 1994; 
Joliot et al., 1991). The polycationic nature of both Pentobra and tobramycin can lead to 
strong electrostatic interactions with anionic components of P. acnes. It is possible that the 
partial anti-inflammatory effects of Pentobra are derived from interference with aspects of 
the toll like receptor-2 (TLR2) pathway, such as NFkB activation, since P. acnes stimulates 
cells through TLR2 (Kim et al., 2002). While the ligands from P. acnes that activate TLR2 
remain under investigation, the interaction of Pentobra with these molecules may reduce 
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inflammation. Furthermore, the polyanionic charge of cell envelope components like 
peptidoglycan can promote complexation with Pentobra, which may prevent detection of 
peptidoglycan by intracellular sensors Nod1 and Nod2. Since inflammation is a key clinical 
feature of acne, the partial anti-inflammatory nature of Pentobra combined with its 
antibacterial activity increases its therapeutic potential.
The immunomodulatory capabilities of membrane-active aminoglycosides suggest potential 
clinical applications. Constraints on the amino acid content of AMPs under-determine the 
full peptide sequence (Schmidt et al., 2011; Schmidt and Wong, 2013), so other functions 
may be written into these peptide-aminoglycoside composites. LL37 is a notable natural 
example as it permeabilizes bacterial membranes and also has multiple immunomodulatory 
functions. In the same spirit, it should be possible to construct future generations of Pentobra 
which are not only potent bactericides against P. acnes, but also complex strongly with P. 
acnes ligands and thereby modulate immune responses.
In conclusion, we have demonstrated the efficacy of a hybrid antibiotic for P. acnes, 
Pentobra, by synergistically combining the antimicrobial functions and specificity 
mechanisms of two different classes of antimicrobials, aminoglycosides and AMPs. 
Pentobra exhibited bactericidal activity against a wide range of P. acnes clinical isolates, 
and effectively killed P. acnes from human donors in microcomedone sebum-rich 
environment in an in vitro assay. Furthermore, various skin cells treated with Pentobra 
showed no adverse effects, suggesting that Pentobra is not only an effective antimicrobial, 
but may also be a safe and less irritating topical agent. Pentobra displayed anti-inflammatory 
activity by suppressing the expression of inflammatory chemokines from monocytes and 
keratinocytes stimulated with P. acnes. The broad bactericidal activity against clinical 
strains of P. acnes in the lipid-rich cutaneous environment, in concert with their potential as 
anti-inflammmatory agents, shows that peptide-aminoglycoside antibiotics designed using 
rules for AMPs are promising therapeutics for infections caused by drug-resistant P. acnes.
Materials and methods
Pentobra
Pentobra is a composite peptide+aminoglycoside compound consisting of a 12AA peptide 
named the pen peptide, which is conjugated to tobramycin. (Schmidt et al., 2014). The five 
amine groups of tobramycin were Boc (tert-butyloxycarbonyl) protected, then the C6″ 
primary hydroxyl of tobramycin-Boc5 was selectively reacted with succinic anhydride to 
produce a terminal carboxyl function. Pen peptide was synthesized manually by solid phase 
synthesis. The carboxyl function extending from tobramycin was coupled with the N-
terminal group of the fully protected resin-anchored pen peptide. The resulting Pentobra was 
cleaved from resin and fully deprotected by cleaving the side-chain protecting groups as 
well as Boc groups on tobramycin with a trifluoroacetic acid mixture containing scavengers. 
Pentobra was finally purified by preparative high-performance liquid chromatography 
(HPLC) and characterized by MALDI-TOF mass spectrometry.
The pen peptide, sequence RQIKIWFQNRRW, was designed with the cationic and 
hydrophobic motif shared by AMPs. It is cationic (+3 from 2 Arg and 1 Lys) and 
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hydrophobic (2 Ile, 2 Trp, and 1 Phe, it is >30% hydrophobic). We designed Pentobra with 
the ability to disrupt bacterial membranes and cross them so that it can bind ribosomes 
through its tobramycin part. To ensure Pentobra permeates cell membranes the pen peptide 
sequence was derived from the 17AA sequence of antennapedia (ANTP) penetratin CPP 
(Derossi et al., 1994), such that the amounts of cationicity and hydrophobicity of the 
composite molecule (pen peptide+tobramycin) are consistent with design principles of CPP 
and AMP sequences (Mishra et al., 2011; Schmidt et al., 2011). Therefore, the sequence of 
the pen peptide was chosen such that the composite pen peptide plus tobramycin would be 
able to permeabilize and penetrate bacterial membranes thereby allowing it to enter bacteria 
cells and bind ribosomes using the mechanism of action from tobramycin.
P. acnes and clinical isolates
P. acnes strain ATCC 6919 was obtained from American Type Culture Collections 
(Manassas, VA). Clinical isolates were obtained from Biodefense and Emerging Infections 
Research Resources Repository (BEI Resources) and from nasal skin microcomedones from 
patients attending the Division of Dermatology outpatient clinic at UCLA, after signed 
written informed consent as approved by the Institutional Review Board at UCLA in 
accordance with the Declaration of Helsinki Principles. The level of endotoxin 
contaminating the P. acnes was quantified with a Limulus Amoebocyte Lysate assay 
(BioWhittaker, Radnor, PA) and found to be <0.1 ng ml−1. P. acnes cultures were grown as 
previously described (Agak et al., 2014). P. acnes strains and clinical isolates used in the 
study are summarized in Table 1.
CFU assay
The CFU assay was performed as described previously (McInturff et al., 2005). P. acnes 
strains (Table 1) were grown under anaerobic conditions in Reinforced Clostridial Medium 
(Oxoid, Basingstroke, England) and collected in mid-log phase. The bacteria were washed 
with the assay buffer (10mM Tris pH 7.4, supplemented with 1% volume Trypticase soy 
broth, Tris-TSB), and enumerated by applying a conversion factor of 7.5 x 107 bacteria per 
mL=1 OD unit at 600 nm. Various concentrations of Pentobra, pen peptide or tobramycin 
were incubated with 3.75 x105 bacteria in a final volume of 100 μL at 37°C for 3 h. After 
incubation, 103–104-fold dilutions were prepared and plated on solid media comprised of 
Brucella broth (BD Biosciences, San Diego, California) with 5% sheep red blood cells 
(Remel, Lenexa, Kansas). Plates were incubated for 4 days at 37°C under anaerobic 
conditions, then individual colonies were counted and the number of CFU per tube was 
calculated.
The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay
Three cell types, PBMCs, Keratinocytes (HaCaT) and Sebocytes cell lines were tested. Cell 
proliferation experiments were performed in 96-well plates (5 replicates). 26 μM of 
Pentobra, pen peptide and Tobramycin treatments were initiated at 24 hours post- seeding 
for 3 days, and assay developed as previously described (Agak et al 2014).
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Electron Microscopy
P. acnes ATCC 6919 at 3x108 CFU/mL were incubated untreated or with 25.7μM of 
Pentobra, pen peptide or tobramycin for 3 hours, washed twice with PBS, and resuspended 
in PBS with 2% glutaraldehyde. The bacteria were fixed for 5 minutes with 0.05% OsO4, 
dehydrated in graded ethanol, and then embedded in Eponate 12 (Ted Pella). 60–70nm slices 
were cut with a Reichert-Jung Ultracut E ultramicrotome, which were picked up on formvar 
coated copper grids. Samples were stained with uranyl acetate and Reynolds lead citrate and 
visualized at 80 kV on a JEOL 100CX electron microscope.
Microcomedone assay
After informed consent was obtained, comedones were collected from human volunteers as 
previously described (McInturff et al., 2005). Briefly, individual plugs were removed from 
the strips with a fine point tweezer and pooled in a microfuge tube. These were then 
resuspended in 200 μL of assay medium (Tris-TSB) until the particulate material was broken 
up into a colloidal suspension. Then, 30 μL of this suspension was combined with either 30 
μL of drug (Pentobra, pen peptide, tobramycin,) or 30 μL of clostridium medium (positive 
control). These were then incubated for 3 h at 37°C in an ambient air incubator. A serial 
dilution of each sample was prepared and 30 μL of each dilution was spotted on Brucella 
blood agar plates and incubated as previously described. The CFU per mL was determined 
by counting.
Monocyte isolation, stimulation and cytokine ELISAs
Monocytes were isolated as previously described (Agak et al., 2014; Qin et al., 2014). 
Adherent monocytes were stimulated (co-treated) with media or P. acnes in the presence of 
tobramycin or Pentobra and cytokine levels measured by ELISA as previously described 
(Agak et al., 2014; Qin et al., 2014) Samples were assayed in triplicates. Results are 
expressed as mean±SD of at least three independent experiments, with monocytes obtained 
from three independent donors.
RNA isolation, cDNA synthesis, and real-time PCR
Monocytes and keratinocytes (HaCaT) were stimulated with media or P. acnes in the 
presence of tobramycin or Pentobra. Total RNA was isolated using Trizol reagent 
(Invitrogen, Carlsbad, CA) and cDNA synthesis and real-time PCR reactions were done as 
previously described (Agak et al., 2014; Qin et al., 2014). The list of primers used in the 
study are summarized in Supplementary Table S1.
Statistical analysis
Results are expressed as the means±SD for the number of separate experiments indicated in 
each case (n≥3). One-way analysis of variance was used to compare variances within groups 
and among them. Post hoc two-tailed Student’s t-test was used for comparison between two 
groups. Significant differences were considered for those probabilities ≤ 5% (P≤ 0.05).
Schmidt et al. Page 9
J Invest Dermatol. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
Acknowledgments
We would like to extend thanks to Marianne Cillufo for assistance with electron microscopy. This work was 
supported by NIH grants 1UO1 AI082192-01 (G.C.L.W.), R01-AR-053542 (J.K.) and T32 Training grant 
AR58921 (G.A.), NSF grants DMR1106106 (G.C.L.W.) and 1-DP2-OD008533 (A.M.K). UCLA has filed a patent 
application on membrane-active aminoglycoside peptide conjugates.
Abbreviations
CPP Cell-penetrating peptide
AMPs Antimicrobial peptides
PBMCs Peripheral blood mononuclear cells
TNF-α Tumor necrosis factor alpha
MCP-1 Monocyte chemoattractant protein1
IP-10 Interferon gamma-induced protein 10
CCL22 C-C motif chemokine 22
CFU Colony forming unit
References
Agak GW, Qin M, Nobe J, et al. Propionibacterium acnes Induces an IL-17 Response in Acne 
Vulgaris that Is Regulated by Vitamin A and Vitamin D. J Invest Dermatol. 2014; 134:366–73. 
[PubMed: 23924903] 
Allison KR, Brynildsen MP, Collins JJ. Metabolite-enabled eradication of bacterial persisters by 
aminoglycosides. Nature. 2011; 473:216–20. [PubMed: 21562562] 
Bals R, Wang X, Wu Z, et al. Human beta-defensin 2 is a salt-sensitive peptide antibiotic expressed in 
human lung. Journal of Clinical Investigation. 1998; 102:874. [PubMed: 9727055] 
Bowdish, D.; Davidson, D.; Hancock, R. Antimicrobial Peptides and Human Disease. Springer; 2006. 
Immunomodulatory properties of defensins and cathelicidins; p. 27-66.
Brogden KA. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nature 
Reviews Microbiology. 2005; 3:238–50. [PubMed: 15703760] 
Bryan L, Kowand S, Van Den Elzen H. Mechanism of aminoglycoside antibiotic resistance in 
anaerobic bacteria: Clostridium perfringens and Bacteroides fragilis. Antimicrobial agents and 
chemotherapy. 1979; 15:7–13. [PubMed: 218500] 
Cooper AJ. Systematic review of Propionibacterium acnes resistance to systemic antibiotics. The 
Medical Journal of Australia. 1998; 169:259–61. [PubMed: 9762064] 
Davis BD. Mechanism of bactericidal action of aminoglycosides. Microbiological reviews. 1987; 
51:341. [PubMed: 3312985] 
Davis BD, Chen LL, Tai PC. Misread protein creates membrane channels: an essential step in the 
bactericidal action of aminoglycosides. Proceedings of the National Academy of Sciences. 1986; 
83:6164–8.
Derossi D, Joliot AH, Chassaing G, et al. The third helix of the Antennapedia homeodomain 
translocates through biological membranes. Journal of Biological Chemistry. 1994; 269:10444–50. 
[PubMed: 8144628] 
Schmidt et al. Page 10
J Invest Dermatol. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Dréno B, Bettoli V, Ochsendorf F, et al. European recommendations on the use of oral antibiotics for 
acne. European Journal of Dermatology. 2004; 14:391–9. [PubMed: 15564203] 
Dürr UH, Sudheendra U, Ramamoorthy A. LL-37, the only human member of the cathelicidin family 
of antimicrobial peptides. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2006; 
1758:1408–25. [PubMed: 16716248] 
Eady E, Gloor M, Leyden J. Propionibacterium acnes resistance: a worldwide problem. Dermatology. 
2003; 206:54–6. [PubMed: 12566805] 
Fischbach MA. Combination therapies for combating antimicrobial resistance. Current opinion in 
microbiology. 2011; 14:519–23. [PubMed: 21900036] 
Fitz-Gibbon S, Tomida S, Chiu B-H, et al. Propionibacterium acnes strain populations in the human 
skin microbiome associated with acne. Journal of investigative dermatology. 2013
Fourmy D, Recht MI, Blanchard SC, et al. Structure of the Ä Site of Escherichia coli 16S Ribosomal 
RNA Complexée! with an Aminoglycoside Antibiotic. Science. 1996; 274:1367. [PubMed: 
8910275] 
Guo L, Lim KB, Gunn JS, et al. Regulation of lipid A modifications by Salmonella typhimurium 
virulence genes phoP-phoQ. Science. 1997; 276:250–3. [PubMed: 9092473] 
Hancock RE, Sahl H-G. Antimicrobial and host-defense peptides as new anti-infective therapeutic 
strategies. Nature biotechnology. 2006; 24:1551–7.
Harder J, Bartels J, Christophers E, et al. Isolation and characterization of human β-defensin-3, a novel 
human inducible peptide antibiotic. Journal of Biological Chemistry. 2001; 276:5707–13. 
[PubMed: 11085990] 
Harder J, Bartels J, Christophers E, et al. A peptide antibiotic from human skin. Nature. 1997; 
387:861. [PubMed: 9202117] 
Hu K, Schmidt NW, Zhu R, et al. A critical evaluation of random copolymer mimesis of homogeneous 
antimicrobial peptides. Macromolecules. 2013; 46:1908–15. [PubMed: 23750051] 
Humphrey S. Antibiotic resistance in acne treatment. Skin Therapy Lett. 2012; 17:1–3. [PubMed: 
23032935] 
Hurdle JG, O’Neill AJ, Chopra I, et al. Targeting bacterial membrane function: an underexploited 
mechanism for treating persistent infections. Nature Reviews Microbiology. 2011; 9:62–75. 
[PubMed: 21164535] 
Joliot A, Pernelle C, Deagostini-Bazin H, et al. Antennapedia homeobox peptide regulates neural 
morphogenesis. Proceedings of the National Academy of Sciences. 1991; 88:1864–8.
Kim J, Ochoa M-T, Krutzik SR, et al. Activation of toll-like receptor 2 in acne triggers inflammatory 
cytokine responses. The Journal of Immunology. 2002; 169:1535–41. [PubMed: 12133981] 
Koprivnjak T, Peschel A. Bacterial resistance mechanisms against host defense peptides. Cellular and 
Molecular Life Sciences. 2011; 68:2243–54. [PubMed: 21560069] 
Li M, Lai Y, Villaruz AE, et al. Gram-positive three-component antimicrobial peptide-sensing system. 
Proceedings of the National Academy of Sciences. 2007; 104:9469–74.
Magnet S, Blanchard JS. Molecular Insights into Aminoglycoside Action and Resistance. Chemical 
reviews. 2004; 105:477–98. [PubMed: 15700953] 
McDowell A, Nagy I, Magyari M, et al. The opportunistic pathogen Propionibacterium acnes: insights 
into typing, human disease, clonal diversification and CAMP factor evolution. PLoS One. 2013; 
8:e70897. [PubMed: 24058439] 
McInturff JE, Wang S-J, Machleidt T, et al. Granulysin-derived peptides demonstrate antimicrobial 
and anti-inflammatory effects against Propionibacterium acnes. Journal of investigative 
dermatology. 2005; 125:256–63. [PubMed: 16098035] 
Mishra A, Lai GH, Schmidt NW, et al. Translocation of HIV TAT peptide and analogues induced by 
multiplexed membrane and cytoskeletal interactions. Proceedings of the National Academy of 
Sciences. 2011; 108:16883–8.
Piérard-Franchimont C, Goffin V, Arrese JE, et al. Lymecycline and Minocycline in Inflammatory 
Acne. Skin Pharmacology and Physiology. 2002; 15:112–9.
Qin M, Pirouz A, Kim MH, et al. Propionibacterium acnes Induces IL-1beta secretion via the NLRP3 
inflammasome in human monocytes. J Invest Dermatol. 2014; 134:381–8. [PubMed: 23884315] 
Schmidt et al. Page 11
J Invest Dermatol. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Rosenfeld Y, Shai Y. Lipopolysaccharide (Endotoxin)-host defense antibacterial peptides interactions: 
role in bacterial resistance and prevention of sepsis. Biochimica et Biophysica Acta (BBA)-
Biomembranes. 2006; 1758:1513–22. [PubMed: 16854372] 
Ross J, Snelling A, Carnegie E, et al. Antibiotic-resistant acne: lessons from Europe. British journal of 
Dermatology. 2003; 148:467–78. [PubMed: 12653738] 
Schmidt NW, Deshayes S, Hawker S, et al. Engineering Persister-Specific Antibiotics with Synergistic 
Antimicrobial Functions. ACS nano. 2014; 8:8786–93. [PubMed: 25130648] 
Schmidt NW, Lis M, Zhao K, et al. Molecular basis for nanoscopic membrane curvature generation 
from quantum mechanical models and synthetic transporter sequences. J Am Chem Soc. 2012a; 
134:19207–16. [PubMed: 23061419] 
Schmidt NW, Mishra A, Lai GH, et al. Criterion for amino acid composition of defensins and 
antimicrobial peptides based on geometry of membrane destabilization. J Am Chem Soc. 2011; 
133:6720–7. [PubMed: 21473577] 
Schmidt NW, Tai KP, Kamdar K, et al. Arginine in α-Defensins: Differental Effects on Bactericidal 
Activity Correspond to Geometry of Membrane Curvature and Peptide-Lipid Phase Behavior. 
Journal of Biological Chemistry. 2012b; 287:21866–72. [PubMed: 22566697] 
Schmidt NW, Wong GC. Antimicrobial peptides and induced membrane curvature: Geometry, 
coordination chemistry, and molecular engineering. Current Opinion in Solid State and Materials 
Science. 2013; 17:151–63. [PubMed: 24778573] 
Scott MG, Davidson DJ, Gold MR, et al. The Human Antimicrobial Peptide LL-37 Is a 
Multifunctional Modulator of Innate Immune Responses. The Journal of Immunology. 2002; 
169:3883–91. [PubMed: 12244186] 
Scott MG, Vreugdenhil AC, Buurman WA, et al. Cutting edge: cationic antimicrobial peptides block 
the binding of lipopolysaccharide (LPS) to LPS binding protein. The Journal of Immunology. 
2000; 164:549–53. [PubMed: 10623792] 
Taber HW, Mueller J, Miller P, et al. Bacterial uptake of aminoglycoside antibiotics. Microbiological 
reviews. 1987; 51:439. [PubMed: 3325794] 
Vicens Q, Westhof E. Crystal structure of a complex between the aminoglycoside tobramycin and an 
oligonucleotide containing the ribosomal decoding a site. Chemistry & biology. 2002; 9:747–55. 
[PubMed: 12079787] 
Vowels B, Yang S, Leyden J. Pro-inflammatory cytokines are inducible by a soluble factor of 
propionibacterium acnes: evidence of peptidoglycan involvement. Journal of investigative 
dermatology. 1995a:104. [PubMed: 7615962] 
Vowels BR, Yang S, Leyden JJ. Induction of proinflammatory cytokines by a soluble factor of 
Propionibacterium acnes: implications for chronic inflammatory acne. Infection and immunity. 
1995b; 63:3158–65. [PubMed: 7542639] 
Walsh C. Molecular mechanisms that confer antibacterial drug resistance. Nature. 2000; 406:775–81. 
[PubMed: 10963607] 
Wang WLL, Everett ED, Johnson M, et al. Susceptibility of Propionibacterium acnes to Seventeen 
Antibiotics. Antimicrobial agents and chemotherapy. 1977; 11:171–3. [PubMed: 836012] 
Williams HC, Dellavalle RP, Garner S. Acne vulgaris. The Lancet. 2012; 379:361–72.
Worthington RJ, Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends 
in biotechnology. 2013; 31:177–84. [PubMed: 23333434] 
Yang L, Gordon VD, Trinkle DR, et al. Mechanism of a prototypical synthetic membrane-active 
antimicrobial: Efficient hole-punching via interaction with negative intrinsic curvature lipids. 
Proceedings of the National Academy of Sciences. 2008; 105:20595–600.
Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 2002; 415:389–95. [PubMed: 
11807545] 
Schmidt et al. Page 12
J Invest Dermatol. Author manuscript; available in PMC 2015 December 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. Pentobra is bactericidal against Propionibacterium acnes
(A) Structure of Pentobra. (B) P. acnes ATCC 6919 was incubated with different 
concentrations of Pentobra, tobramycin, or pen peptide (0–52 μM) for 3 hours and tested for 
bactericidal activity using the CFU assay. Data show average CFU from three independent 
experiments (n = 3), error bars are ± SEM.
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Figure 2. Pentobra is bactericidal against a broad range of P. acnes strains
CFU assay results for Pentobra, pen peptide and tobramycin at varying concentrations (0–26 
μM) incubated with P. acnes clinical isolates (A) HL063PA2 (health-associated), (B) 
HL005PA1 (health-associated) (C) HL110PA4 (health-associated), (D) HL053PA2 (acne-
associated), (E) HL043PA1 (acne-associated) and (F) HL110PA1 (acne-associated) for 3 h. 
Data from one experiment is shown and the trends in antimicrobial activity of the 
compounds and activity differences between compounds are representative of three 
independent experiments.
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Figure 3. EM studies show Pentobra acts on P. acnes cell membranes
Representative TEM micrographs of (A) untreated P. acnes control, (B) P. acnes after 3 h 
incubation with 25.7μM Pentobra, (C) P. acnes after 3 h incubation with 25.7μM pen 
peptide, and, (D) P. acnes after 3 h incubation with 25.7μM tobramycin. TEM were imaged 
at 10K magnification (top), 36K (bottom left), and 72K (bottom right). Compared with 
untreated control, the bacteria exposed to Pentobra and pen peptide exhibit cellular 
differences indicative of stresses on the membrane. Complete lysis of the cell membrane 
occurs, and the envelope boundary is now decorated with numerous blebbing events (bottom 
images in B and C). Scale bar = 5nm.
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Figure 4. Pentobra is bactericidal in the sebaceous microcomedone environment
Antimicrobial activity against P. acnes in the microcomedones was determined using a CFU 
assay. Pentobra, pen peptide or tobramycin (0 – 102 μM) were incubated for 3 hours in 
collected lipid-rich microcomedones isolated from four donors’ faces (A – D) using deep 
cleaning pore strips. Pentobra exhibits strong bactericidal activity while tobramycin and pen 
peptide did not. Data in A represent mean ±SD of three experiments using microcomedones 
extracted on different days from the same donor. Data in B, C, and D are each from a 
different donor.
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Figure 5. Immunomodulatory effects of Pentobra on human monocytes and keratinocyte cell line 
stimulated with P. acnes
Adherent monocytes (A–D)and HaCaT (E–H) cells were cultured (2–3 x 106/ml) with P. 
acnes in the presence of Pentobra (26 μM), and tobramycin (26 μM)). MCP-1 (A and E), 
CCL22 (B and F), IP-10 (C and G), and IL-12p40 (D and H) mRNA expression was 
analyzed 24 hours following P. acnes stimulation. Gene expression was normalized to the 
housekeeping genes GAPDH and quantified by the comparative method 2−ΔΔCT. Each panel 
is representative of three independent donors and experiments. Data represent mean ±SD 
(***p ≤ 0.001). Primers used in the study are listed in supplementary Table S1.
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Table 1
P. acnes clinical isolates used in the study
Clinical isolate Phylotype Ribotype (RT) Disease association
ATCC 6919 IA-1 RT1 Neutral/commensala
HL005PA1 IA-1 RT1 Healthyb
HL043PA1 IA-2 RT5 Acnec
HL053PA2 IB-1 RT8 Acne
HL063PA1 IA-1 RT1 healthy
HL110PA1 IB-1 RT8 Acne
HL110PA4 II RT6 healthy
a
P. acnes laboratory strain
bClinical isolates associated with healthy skin
cClinical isolates associated with acne skin
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